{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:20Z","timestamp":1793773820364,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s12325-024-02822-z","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T03:01:45Z","timestamp":1710730905000},"page":"1938-1952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase\u00a0Inhibitor"],"prefix":"10.1007","volume":"41","author":[{"given":"Gilles","family":"Salles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-3699","authenticated-orcid":false,"given":"Jenny M. H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Kloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia T.","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"2822_CR1","unstructured":"American Cancer Society. Types of B-cell lymphoma 2019 [updated January 29, 2019]. https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html. Accessed 2023 Aug 27."},{"issue":"6","key":"2822_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/2040620711412418","volume":"2","author":"DJ Inwards","year":"2011","unstructured":"Inwards DJ, Witzig TE. Initial therapy of mantle cell lymphoma. Ther Adv Hematol. 2011;2(6):381\u201392.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2822_CR3","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.3747\/co.26.4345","volume":"26","author":"C Owen","year":"2019","unstructured":"Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233\u201340.","journal-title":"Curr Oncol"},{"issue":"1","key":"2822_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","volume":"10","author":"M Wang","year":"2017","unstructured":"Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2822_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","volume":"182","author":"P McKay","year":"2018","unstructured":"McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46\u201362.","journal-title":"Br J Haematol"},{"issue":"2","key":"2822_CR6","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u201371.","journal-title":"Haematologica"},{"issue":"4","key":"2822_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684\u20138.","journal-title":"Br J Haematol"},{"issue":"4","key":"2822_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578\u201387.","journal-title":"Br J Haematol"},{"issue":"12","key":"2822_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559\u201363.","journal-title":"Blood"},{"issue":"4","key":"2822_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/bjh.18519","volume":"202","author":"G Hess","year":"2022","unstructured":"Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. 2022;202(4):749\u201359.","journal-title":"Br J Haematol"},{"issue":"14","key":"2822_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"key":"2822_CR12","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023:JCO2102370.","DOI":"10.1200\/JCO.21.02370"},{"key":"2822_CR13","unstructured":"US Food and Drug Administration. TECARTUS (brexucabtagene autoleucel) prescribing information 2021 [updated October 2021]. https:\/\/www.fda.gov\/media\/140409\/download?attachment.  Accessed 2023 Aug 27."},{"key":"2822_CR14","unstructured":"European Medicines Agency. Tecartus: EPAR\u2014Product information 2023 [updated November 28, 2023]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecartus.  Accessed 2023 Aug 27."},{"key":"2822_CR15","unstructured":"Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. J Clin Oncol. 2023:101200JCO2300562."},{"key":"2822_CR16","unstructured":"US Food and Drug Administration. JAYPIRCA (pirtobrutinib) prescribing information 2023 [updated January 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216059Orig1s000Corrected_lbl.pdf.  Accessed 2023 Aug 27."},{"key":"2822_CR17","unstructured":"European Medicines Agency. Jaypirca : EPAR\u2014Public assessment report 2023 [updated November 20, 2023; cited 2023 December 4]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jaypirca."},{"issue":"27","key":"2822_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201367.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"2822_CR19","doi-asserted-by":"publisher","first-page":"9368","DOI":"10.1182\/blood-2022-159425","volume":"140","author":"ML Wang","year":"2022","unstructured":"Wang ML, Shah NN, Jurczak W, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed\/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase\u00a01\/2 BRUIN study. Blood. 2022;140(Supplement 1):9368\u201372.","journal-title":"Blood"},{"key":"2822_CR20","doi-asserted-by":"crossref","unstructured":"Shah NN, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): updated results and subgroup analysis from the phase\u00a01\/2 BRUIN study with 2\u00a0years of survival follow-up. In: Presented at American Society of clinical oncology 59th annual meeting; Chicago, IL; June 2\u20136, 2023. 2023.","DOI":"10.1016\/j.htct.2023.09.691"},{"key":"2822_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2023-181627","volume":"142","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase\u00a01\/2 BRUIN study. Blood. 2023;142:981.","journal-title":"Blood"},{"key":"2822_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"2822_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Dec Mak. 2018;38(2):200\u201311.","journal-title":"Med Dec Mak"},{"issue":"3","key":"2822_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515\u201326.","journal-title":"Biometrika"},{"issue":"1","key":"2822_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","volume":"77","author":"TM Therneau","year":"1990","unstructured":"Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77(1):147\u201360.","journal-title":"Biometrika"},{"key":"2822_CR26","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016."},{"issue":"7","key":"2822_CR27","doi-asserted-by":"publisher","first-page":"S609","DOI":"10.1016\/j.jval.2022.04.1695","volume":"25","author":"M Dreyling","year":"2022","unstructured":"Dreyling M, Shah B, Wu JJ, et al. SA29 efficacy outcomes following treatment with Bruton tyrosine kinase inhibitors (BTKI) for relapsed\/refractory mantle cell lymphoma (R\/R MCL): a literature-based meta-analysis. Value Health. 2022;25(7):S609\u201310.","journal-title":"Value Health"},{"key":"2822_CR28","doi-asserted-by":"publisher","first-page":"S461","DOI":"10.1016\/S2152-2650(23)01377-0","volume":"23","author":"M Dreyling","year":"2023","unstructured":"Dreyling M, Shah B, Wu J, et al. MCL-373 unmet need in relapsed\/refractory (RR) mantle cell lymphoma (MCL) post-Bruton tyrosine kinase inhibitor (BTKi): systematic literature review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2023;23:S461\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2822_CR29","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594\u2013606.","journal-title":"J Clin Oncol"},{"key":"2822_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2023-179269","volume":"142","author":"S Kambhampati","year":"2023","unstructured":"Kambhampati S, Ahmed N, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics. Blood. 2023;142:107.","journal-title":"Blood"},{"key":"2822_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1182\/blood-2021-148626","volume":"138","author":"C Herbaux","year":"2021","unstructured":"Herbaux C, Bret C, Di Blasi R, et al. Kte-X19 in relapsed or refractory mantle-cell lymphoma, a \u201creal-life\u201d study from the Descar-T Registry and Lysa Group. Blood. 2021;138:743.","journal-title":"Blood"},{"key":"2822_CR32","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1182\/blood-2023-182415","volume":"142","author":"G Hess","year":"2023","unstructured":"Hess G, Vucinic V, Rejeski K, et al. Real world results of brexucabtagene autoleucel for patients with relapsed\/refractory mantle cell lymphoma-first German\/Swiss analysis. Blood. 2023;142:4394.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2822_CR33","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1182\/blood-2022-165031","volume":"140","author":"MA O'Reilly","year":"2022","unstructured":"O\u2019Reilly MA, Sanderson R, Wilson W, et al. Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: real-world outcomes In the United Kingdom. Blood. 2022;140(Suppl 1):7519\u201321.","journal-title":"Blood"},{"key":"2822_CR34","doi-asserted-by":"crossref","unstructured":"Hess G, Dreyling M, Oberic L, et al. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma. Leukemia Lymphoma. 2024;65(1):14\u201325.","DOI":"10.1080\/10428194.2023.2268228"},{"issue":"1","key":"2822_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01755-5","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang D-H, Zhao H-B. CAR T-cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023;22(1):1\u201319.","journal-title":"Mol Cancer"},{"key":"2822_CR36","doi-asserted-by":"crossref","unstructured":"Cohen JB, Shah NN, Jurczak W, et al. 981 Pirtobrutinib in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase\u00a01\/2 BRUIN Study. American Society of Hematology Annual Meeting; 2023.","DOI":"10.1182\/blood-2023-181627"},{"issue":"5","key":"2822_CR37","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874.","journal-title":"Haematologica"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02822-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02822-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02822-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T17:12:16Z","timestamp":1714151536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02822-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2822"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02822-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gilles Salles has received consulting fees from Abbvie, Celgene\/BMS, Epizyme, Genmab, Incyte, Janssen, Kite, a Gilead Company, Loxo, Milteniy, Molecular Partners, Morphosys, Nordic Nanovector, Novartis, Rapt, and Takeda; has received payment or honoraria for speaking in symposium from Bayer, Epizyme, and Regeneron; has participated on a Data Safety Monitoring board or Advisory Board for Beigene; and has stock or stock options from Owkin. Jenny M.H. Chen, Ina Zhang, Dylan Maciel, Keith Chan, and Sam Keeping are employees of PRECISIONheor, funded by Kite, a Gilead Company for this study. Fabio Kerbauy declares no competing interests. James J. Wu is an employee of Kite, a Gilead Company; has received honoraria from the Patient-Centered Outcomes Research Institute (PCORI), both as a member of the Rare Disease Advisory Panel, and as a grants reviewer for the Improving Methods Program; has received travel\/meeting support from Kite, a Gilead Company, and Amgen; owns stock in Gilead Sciences, Amgen, Abbott, AbbVie, Pfizer, Roche, Curis, Avid Biosciences, Evofem, Lensar, VBI Vaccines, and Viracta Therapeutics. Sally W. Wade has received consulting fees from Kite, a Gilead Company, Abbvie, and Johnson & Johnson. Fabio R. Kerbauy declares no competing interests. Ana Nunes is an employee of Gilead Sciences Europe; own stocks in Gilead Sciences and Amgen; and has received support for attending meetings and\/or travel from Kite, a Gilead Company. Chaoling Feng is an employee of Kite, A Gilead Company; own stocks in Gilead Sciences, Boston Scientific, and has received support for attending meetings and\/or travel from Kite, a Gilead Company. Ioana Kloos is an employee of Kite, A Gilead Company; own stocks in Gilead Sciences; and has been compensated for a leadership role (such as officer or member of a board of directors) for Kite, A Gilead Company. Weimin Peng is an employee of Kite, a Gilead Company; and owns stock in Gilead Sciences. Julia T. Snider is an employee of Kite, a Gilead Company; owns stock in Gilead Sciences. Bijal Shah has received consultant and education fees from Amgen, Pfizer, Novartis, BMS\/Celgene\/Juno, Kite, a Gilead company, Precision Biosciences, Jazz, Beigene, Adaptive, Century Therapeutics, and Autolus; and clinical trial grants from Kite, a Gilead company, Jazz, and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Results presented in this article are based on a retrospective analysis of data from published studies, and therefore no institutional board review was required. Review boards at participating institutions approved the ZUMA-2 and BRUIN trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}